Lidds AB (LIDDS) - Total Liabilities
Based on the latest financial reports, Lidds AB (LIDDS) has total liabilities worth Skr491.00K SEK (≈ $52.84K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore LIDDS long-term investments to assets to see how much of total assets are deployed in long-term investments.
Lidds AB - Total Liabilities Trend (2010–2024)
This chart illustrates how Lidds AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see LIDDS total assets.
Lidds AB Competitors by Total Liabilities
The table below lists competitors of Lidds AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
finnCap Group PLC
LSE:CAV
|
UK | GBX49.24 Million |
|
Palace Capital PLC
LSE:PCA
|
UK | GBX2.36 Million |
|
Israel Opportunity - Energy Resources LP
TA:ISOP-L
|
Israel | ILA259.00K |
|
Wildpack Beverage Inc
V:CANS
|
Canada | CA$141.24 Million |
|
KOYJ Co. Ltd
KQ:121850
|
Korea | ₩20.66 Billion |
|
Reco International Group Inc
V:RGI
|
Canada | CA$3.57 Million |
|
BLUERUSH Media Group Corp
V:BTV
|
Canada | CA$7.19 Million |
|
Imobiliária Construtora Grão Pará S.A.
LS:GPA
|
Portugal | €27.13 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Lidds AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Lidds AB (LIDDS) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 3.53 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lidds AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lidds AB (2010–2024)
The table below shows the annual total liabilities of Lidds AB from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr1.98 Million ≈ $212.97K |
-47.31% |
| 2023-12-31 | Skr3.76 Million ≈ $404.21K |
-64.47% |
| 2022-12-31 | Skr10.57 Million ≈ $1.14 Million |
+49.58% |
| 2021-12-31 | Skr7.07 Million ≈ $760.52K |
-37.99% |
| 2020-12-31 | Skr11.40 Million ≈ $1.23 Million |
+91.05% |
| 2019-12-31 | Skr5.96 Million ≈ $641.91K |
+22.76% |
| 2018-12-31 | Skr4.86 Million ≈ $522.91K |
+36.48% |
| 2017-12-31 | Skr3.56 Million ≈ $383.16K |
-58.06% |
| 2016-12-31 | Skr8.49 Million ≈ $913.69K |
+229.98% |
| 2015-12-31 | Skr2.57 Million ≈ $276.89K |
+10.96% |
| 2014-12-31 | Skr2.32 Million ≈ $249.55K |
+47.07% |
| 2013-12-31 | Skr1.58 Million ≈ $169.68K |
-55.24% |
| 2012-12-31 | Skr3.52 Million ≈ $379.11K |
+107.08% |
| 2011-12-31 | Skr1.70 Million ≈ $183.08K |
+42.38% |
| 2010-12-31 | Skr1.19 Million ≈ $128.59K |
-- |
About Lidds AB
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemoth… Read more